Masimo Co. (NASDAQ:MASI) Receives Average Rating of “Moderate Buy” from Analysts

Masimo Co. (NASDAQ:MASI) has earned an average rating of “Moderate Buy” from the six research firms that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12-month target price among analysts that have updated their coverage on the stock in the last year is $194.80.

Several research firms have recently weighed in on MASI. Stifel Nicolaus reaffirmed a “buy” rating and issued a $190.00 price objective (up from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Raymond James lifted their price objective on Masimo from $170.00 to $194.00 and gave the company an “outperform” rating in a research note on Friday, December 27th. Needham & Company LLC reaffirmed a “hold” rating on shares of Masimo in a research note on Wednesday, February 26th. Piper Sandler boosted their price target on Masimo from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th. Finally, Wells Fargo & Company boosted their price target on Masimo from $193.00 to $205.00 and gave the stock an “overweight” rating in a research report on Wednesday, February 26th.

Masimo Stock Up 1.5 %

MASI opened at $168.21 on Monday. The company has a debt-to-equity ratio of 0.50, a current ratio of 2.01 and a quick ratio of 1.11. The stock has a market capitalization of $9.07 billion, a price-to-earnings ratio of 116.01 and a beta of 1.03. The business has a 50-day moving average of $174.84 and a two-hundred day moving average of $157.94. Masimo has a 12 month low of $101.61 and a 12 month high of $194.88.

Masimo (NASDAQ:MASI) last released its quarterly earnings data on Tuesday, February 25th. The medical equipment provider reported $1.80 earnings per share for the quarter, beating the consensus estimate of $1.42 by $0.38. The business had revenue of $600.70 million for the quarter, compared to analyst estimates of $593.35 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. On average, research analysts expect that Masimo will post 4.1 earnings per share for the current year.

Insider Buying and Selling at Masimo

In other news, COO Bilal Muhsin sold 30,000 shares of the business’s stock in a transaction that occurred on Monday, March 10th. The stock was sold at an average price of $167.49, for a total value of $5,024,700.00. Following the completion of the sale, the chief operating officer now directly owns 24,172 shares in the company, valued at approximately $4,048,568.28. The trade was a 55.38 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Craig B. Reynolds sold 2,053 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $166.13, for a total value of $341,064.89. Following the completion of the sale, the director now owns 16,581 shares of the company’s stock, valued at $2,754,601.53. This trade represents a 11.02 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.70% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Masimo

A number of institutional investors have recently made changes to their positions in MASI. Assetmark Inc. grew its stake in Masimo by 12.7% during the 3rd quarter. Assetmark Inc. now owns 1,183 shares of the medical equipment provider’s stock worth $158,000 after buying an additional 133 shares during the last quarter. Crossmark Global Holdings Inc. grew its stake in Masimo by 14.4% during the 3rd quarter. Crossmark Global Holdings Inc. now owns 3,248 shares of the medical equipment provider’s stock worth $433,000 after buying an additional 409 shares during the last quarter. Oppenheimer Asset Management Inc. bought a new position in Masimo during the 3rd quarter worth $478,000. KBC Group NV grew its stake in Masimo by 17.3% during the 3rd quarter. KBC Group NV now owns 1,280 shares of the medical equipment provider’s stock worth $171,000 after buying an additional 189 shares during the last quarter. Finally, CIBC Asset Management Inc bought a new position in Masimo during the 3rd quarter worth $206,000. 85.96% of the stock is currently owned by institutional investors.

About Masimo

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.